Analysis of the Marketing Approval of Pediatric Drugs in the United States and Its Enlightenment to Pedia tric Drug Use Guarantee in China
- VernacularTitle:美国儿童药品上市审批情况分析及其对我国儿童用药保障工作的启示
- Author:
Yajun WANG
1
,
2
;
Rong HAN
1
;
Zhihua YUE
3
;
Xinwen XU
4
;
Zhigang ZHAO
1
Author Information
1. Dept. of Pharmacy，Beijing Tiantan Hospital，Capital Medical University，Beijing 100070，China
2. College of Pharmacy，Capital Medical University，Beijing 100069，China
3. Dept. of Chemical Drug，Chinese Pharmacopoeia Commission，Beijing 100061，China
4. Dept. of Secretariat，Safe Medication for Children Branch of China Medical News and Information Association，Beijing 101200，China
- Publication Type:Journal Article
- Keywords:
Pediatric drugs;
Marketing approval;
Policy
- From:
China Pharmacy
2021;32(2):133-138
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To provide sugge stions for improving the variety of pediatric drugs and ensuring the safety of pediatric drug use in China. METHODS ：The historical evolution of laws and regulations on the marketing approval of pediatric drugs in the United States and the implementation results of relevant policies were summarized. Combined with the current situation of the development of pediatric drugs in China ，some suggestions were put forward to ensure the accessibility and safety of pediatric drug use in China. RESULTS & CONCLUSIONS ：Since 1994，the United States had issued a series of laws and regulations to encourage the development of pediatric drugs. At present ，the marketing approval of pediatric drugs were mainly based on the two laws of Best Pediatric Drug Act（BPCA）and Pediatric Research Equality Act （PREA）. From 1998 to 2019，the amount of supplements of pediatric drug information in drug instructions of the United States showed a fluctuating growth. As of April 2020，854 kinds of drugs had been modified in pediatric instructions ，792 of which had been carried out post marketing pediatric clinical research ，and the problem of incomplete pediatric instructions had also been greatly improved. At present ，China’s policies on pediatric drugs mainly included encouraging R&D innovation ，giving priority to review and approval ，and strengthening R&D technical guidance. Although certain achievements had been made ，there were still some problems ，such as imperfect policies and regulations ，and great difficulties carrying out pediatric drug clinical trials. It is suggested that our country should draw lessons from the American regulations on pediatric drugs ，pediatric research and the catalogue of pediatric drugs ，and establish a system and catalogue of ped iatric drug use suitable for China ’s national conditions ，so as to improve the effectiveness ，safety and accessibilityof pediatric drugs.
